Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Other opioids

Updated · Methodology

Mechanism

In its list of pharmacokinetic interactions, the acenocoumarol summary of product characteristics (SmPC) names tramadol among drugs that can potentiate the anticoagulant effect of acenocoumarol. It does not explain the mechanism (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The tramadol SmPC reports cases of a raised international normalised ratio (INR) with major bleeding and ecchymosis when tramadol is combined with coumarin derivatives (tramadol SmPC, AEMPS). Acenocoumarol is a coumarin derivative (acenocoumarol SmPC, AEMPS). The US tramadol label has data for warfarin only: rare post-marketing reports of an altered warfarin effect, including prolonged prothrombin times (tramadol prescribing information, US Food and Drug Administration, FDA).

Symptoms

The main risk is bleeding from an excessive acenocoumarol effect. With coumarin derivatives, the tramadol summary of product characteristics (SmPC) reports cases of a raised international normalised ratio (INR) with major bleeding and ecchymosis (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS). Tachycardia, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain can also occur (acenocoumarol SmPC, AEMPS).

Management

The combination is not contraindicated but needs caution (tramadol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Close and frequent coagulation checks, for example twice a week, are needed both when tramadol is added to acenocoumarol and when it is stopped (acenocoumarol SmPC, AEMPS). For warfarin, the US tramadol label asks for frequent re-evaluation of the prothrombin time and warfarin dose adjustment as needed (tramadol prescribing information, US Food and Drug Administration, FDA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose of acenocoumarol is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. Restart acenocoumarol once the INR is back in the target range (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Tramadol